|
|
|
|
||
RVX HAS JOINED PARTNERING 360IS RVX REALLY IN SERIOUS DISSCUSIONS WITH PHARMAS, WHY WOULD THEY POST THE FOLLOWING ON 360? THOUGHTS? " RVX-208 our lead ApoA-I production small molecule, is the first epigenetic BET inhibitor to be tested in humans for the treatment of atherosclerosis. We are targeting the 30 million high-risk cardi... Sector: Cardiovascular - Partnering status: Available for out-licensing Epigenetics Platform: Diabetes Mellitus Resverlogix Corp. Diabetes mellitus (DM) is the most common endocrine disease in the world. A primary defect in DM is the inability of the pancreas to provide enough insulin for the body, thus leading to increased b... Sector: Endocrine, nutritional and metabolic diseases - Partnering status: Available for out-licensing Epigenetics Platform: Neurodegenerative Diseases Resverlogix Corp. Epidemiological and mechanistic evidence indicate a link between low ApoA-I/HDL and neurodegenerative diseases such as dementia and Alzheimer’s disease (“AD”). Our lead molecule RVX-208 has illustr... Sector: Diseases of the nervous system - Partnering status: Available for out-licensing " |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
25887 | Re: RVX HAS JOINED PARTNERING 360 | Fundamentals6 | 1 | 1/12/2015 3:46:24 PM |
25888 | Re: RVX HAS JOINED PARTNERING 360 | sling5 | 0 | 1/12/2015 9:20:18 PM |